Literature DB >> 18187921

Effect of synthetic cell-penetrating peptides on TrkA activity in PC12 cells.

Munetaka Hirose1, Mayumi Takatori, Yoshihiro Kuroda, Mineo Abe, Eri Murata, Tetsuro Isada, Koyo Ueda, Kenji Shigemi, Masayuki Shibazaki, Fumihiro Shimizu, Masashi Hirata, Keita Fukazawa, Masahiro Sakaguchi, Kyoko Kageyama, Yoshifumi Tanaka.   

Abstract

As TrkA, a high-affinity receptor of nerve growth factor (NGF), is a potential target for relieving uncontrolled inflammatory pain, an effective inhibitor of TrkA has been required for pain management. To identify a specific inhibitor of TrkA activity, we designed cell-penetrating peptides combined with amino-acid sequences in the activation loop of TrkA to antagonize tyrosine kinase activity. To select a peptide inhibiting TrkA activity, we examined the effect of cell-penetrating peptides on tyrosine kinase activity of recombinant TrkA in vitro and studied their effects on NGF-stimulated neurite outgrowth and protein phosphorylation in PC12 cells. Thereafter we investigated the effect of the selected peptide on NGF-stimulated TrkA activity and the expression of transient receptor potential channel 1 in PC12 cells. The selected peptide inhibited TrkA activity, but did not inhibit tyrosine kinase activities of other receptor-type tyrosine kinases in vitro. It also suppressed NGF-stimulated responses in PC12 cells. The selected synthetic cell-penetrating peptide antagonizing TrkA function would be a candidate for inflammatory pain therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18187921     DOI: 10.1254/jphs.fpz070263

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  4 in total

1.  Effects of TrkA inhibitory peptide on cancer-induced pain in a mouse melanoma model.

Authors:  Mari Tabata; Eri Murata; Koyo Ueda; Nahoko Kato-Kogoe; Yoshihiro Kuroda; Munetaka Hirose
Journal:  J Anesth       Date:  2012-05-22       Impact factor: 2.078

2.  Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231.

Authors:  Sonia Aroui; Narendra Ram; Florence Appaix; Michel Ronjat; Abderraouf Kenani; Fabienne Pirollet; Michel De Waard
Journal:  Pharm Res       Date:  2008-12-13       Impact factor: 4.200

3.  Bioportide: an emergent concept of bioactive cell-penetrating peptides.

Authors:  John Howl; Sabine Matou-Nasri; David C West; Michelle Farquhar; Jiřina Slaninová; Claes-Göran Ostenson; Matjaz Zorko; Pernilla Ostlund; Shant Kumar; Ulo Langel; Jane McKeating; Sarah Jones
Journal:  Cell Mol Life Sci       Date:  2012-04-20       Impact factor: 9.261

4.  A C-terminal cysteine residue is required for peptide-based inhibition of the NGF/TrkA interaction at nM concentrations: implications for peptide-based analgesics.

Authors:  Andrew J Poole; Laura Frigotto; Matthew E Smith; Claudia Baar; Gabriela Ivanova-Berndt; Agnes Jaulent; Catherine Stace; Christopher G Ullman; Anna V Hine
Journal:  Sci Rep       Date:  2019-01-30       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.